PSMA was originally targeted by the 111In-labeled monoclonal antibody 7E11-C5 (ProstaScint®; Cytogen Corporation, Princeton, NJ) which specifically binds to the PSMA+ human adenocarcinoma cell line LNCaP [7]. The gene discussed is FOLH1; the disease is adenocarcinoma.